Director Arlene Morris of Cogent Biosciences, Inc. filed a Form 4 on August 31, 2026, reporting the exercise of two stock options and the subsequent sale of all resulting common stock shares on August 27, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Option exercise (first tranche): Morris exercised 41,927 fully vested stock options at an exercise price of $5.64 per share, acquiring 41,927 shares of common stock.
  • Option exercise (second tranche): Morris exercised 3,583 fully vested stock options at an exercise price of $2.52 per share, acquiring 3,583 shares of common stock.
  • Sale of 42,349 shares: Sold at a weighted average price of $37.0925 per share, with individual transaction prices ranging from $36.46 to $37.45.
  • Sale of 3,161 shares: Sold at a weighted average price of $37.5396 per share, with individual transaction prices ranging from $37.46 to $37.65.
  • Zero shares remaining: Following all reported transactions, Morris holds 0 shares of common stock directly.
  • Rule 10b5-1 plan: All transactions were effected pursuant to a trading plan adopted by Morris on May 28, 2026.

Arlene Morris Exercises and Sells All Cogent Biosciences Stock Options on August 27, 2026

According to the filing, Arlene Morris, a director of Cogent Biosciences, Inc. (NASDAQ:COGT), executed a series of transactions on August 27, 2026, under a Rule 10b5-1 trading plan she adopted on May 28, 2026. The transactions involved the exercise of two separate tranches of fully vested stock options and the immediate sale of all resulting common shares.

The first option tranche consisted of 41,927 stock options with an exercise price of $5.64 per share, with an expiration date of June 4, 2035, according to the filing. Following this exercise, Morris acquired 41,927 shares of common stock. She then sold 42,349 shares at a weighted average price of $37.0925, with individual sale prices ranging from $36.46 to $37.45 per share. The second option tranche consisted of 3,583 stock options with an exercise price of $2.52 per share, expiring June 9, 2030. The filing notes that after exercising these options, Morris sold the remaining 3,161 shares at a weighted average price of $37.5396, with individual prices ranging from $37.46 to $37.65 per share.

After all reported transactions, the filing discloses that Morris directly holds 0 shares of common stock and 0 derivative securities. The filing notes that 2,773 stock options under the $5.64 tranche remain beneficially owned following the reported exercise. The filing was signed by Evan D. Kearns as Attorney-in-Fact on August 31, 2026.

What Was Disclosed

The Form 4 discloses that director Arlene Morris exercised two fully vested stock option grants totaling 45,510 shares and sold all resulting common stock on August 27, 2026, under a pre-established Rule 10b5-1 plan, leaving her with no directly held common shares.